Goldman Sachs Maintains Sell on 10x Genomics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Sell' rating on 10x Genomics (NASDAQ:TXG) but raised the price target from $25 to $30.

July 13, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a 'Sell' rating on 10x Genomics but raised the price target from $25 to $30.
The 'Sell' rating maintained by Goldman Sachs indicates a negative outlook for 10x Genomics. However, the increase in price target from $25 to $30 suggests that the analyst sees some potential for the stock's price to rise in the short term, despite the overall negative rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100